Department of Pharmacy Practice, Wilkes University, Wilkes-Barre, PA, USA.
Ann Pharmacother. 2011 Jan;45(1):23-30. doi: 10.1345/aph.1P384. Epub 2011 Jan 4.
Previous trials investigating preoperative statin use for prevention of acute kidney injury following cardiovascular surgery were limited to patients undergoing a specific procedure and many used nonconsensus definitions of acute kidney injury.
To use a consensus definition of acute kidney injury for evaluating the association of preoperative statin use with the development of acute kidney injury following cardiac surgery utilizing cardiopulmonary bypass.
We retrospectively evaluated a cohort of 667 patients ≥18 years who underwent any cardiac surgery on cardiopulmonary bypass between April 2007 and May 2009 at Mercy Hospital in Scranton, PA. Patients were excluded if they were receiving preoperative renal replacement therapy, had stage 5 chronic kidney disease, or did not have a postoperative serum creatinine level assessed. The primary outcome was the odds of developing acute kidney injury given the use of preoperative statins. Acute kidney injury was defined based on the Acute Kidney Injury Network criteria as either an absolute increase in serum creatinine of ≥0.3 mg/dL or 1.5 times baseline, or the need for postoperative renal replacement therapy.
The final analysis included 563 patients; 356 were receiving preoperative statins. The incidence of acute kidney injury was 35.1% in the statin group and 26.1% in the non-statin group. On univariate analysis statins were associated with an increase in the odds of acute kidney injury (OR 1.53; 95% CI 1.05 to 2.24). Multivariate logistic regression did not demonstrate an association of statins with acute kidney injury (OR 1.36; 95% CI 0.904 to 2.05). Repeating the analysis using 312 propensity score-matched patients also showed no association of statins with acute kidney injury (OR 1.17; 95% CI 0.715 to 1.93).
Our findings do not support the hypothesis that preoperative statin use is associated with a decrease in the incidence of acute kidney injury following cardiac surgery utilizing cardiopulmonary bypass.
先前关于术前他汀类药物使用预防心血管手术后急性肾损伤的试验仅限于接受特定手术的患者,并且许多试验使用了急性肾损伤的非共识定义。
使用急性肾损伤的共识定义来评估术前他汀类药物使用与体外循环下心脏手术后急性肾损伤的发展之间的关联。
我们回顾性评估了 2007 年 4 月至 2009 年 5 月期间在宾夕法尼亚州斯克兰顿的 Mercy 医院接受体外循环下任何心脏手术的 667 名年龄≥18 岁的患者。如果患者正在接受术前肾脏替代治疗、患有 5 期慢性肾脏疾病或术后未评估血清肌酐水平,则将其排除在外。主要结局是使用术前他汀类药物的情况下发生急性肾损伤的可能性。急性肾损伤根据急性肾损伤网络标准定义为血清肌酐绝对增加≥0.3mg/dL 或增加 1.5 倍基线值,或需要术后肾脏替代治疗。
最终分析包括 563 名患者;356 名患者正在接受术前他汀类药物治疗。他汀类药物组的急性肾损伤发生率为 35.1%,非他汀类药物组为 26.1%。在单变量分析中,他汀类药物与急性肾损伤的几率增加相关(OR 1.53;95%CI 1.05 至 2.24)。多变量逻辑回归未显示他汀类药物与急性肾损伤之间存在关联(OR 1.36;95%CI 0.904 至 2.05)。使用 312 名倾向评分匹配患者重复分析也未显示他汀类药物与急性肾损伤之间存在关联(OR 1.17;95%CI 0.715 至 1.93)。
我们的发现不支持术前他汀类药物使用与体外循环下心脏手术后急性肾损伤发生率降低相关的假设。